Clinical Trials
116 trialsNAVIGATE
Bayer
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
National Cancer Center Hospital East
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
ACUPUNCTURE
Wake Forest University Health Sciences
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
University Health Network, Toronto
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
Memorial Sloan Kettering Cancer Center
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
M.D. Anderson Cancer Center
EARN
Washington University School of Medicine
Arginine/Omega-3 Fatty Acids/Nucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
Institut du Cancer de Montpellier - Val d'Aurelle
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
University of Washington
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
University of Chicago
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
University of Washington
Activity of Sorafenib in Salivary Gland Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Canadian Cancer Trials Group
Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor
Canadian Cancer Trials Group
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer
Eastern Cooperative Oncology Group
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
Eastern Cooperative Oncology Group
Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
Eastern Cooperative Oncology Group
LUPSA
Radboud University Medical Center
DUET-2
Xencor, Inc.
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
Roswell Park Cancer Institute
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
MacroGenics
NISCAHN
UNICANCER
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
University of Chicago
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
National Cancer Institute (NCI)
Stereotactic Body Radiotherapy for Head and Neck Tumors
Mercy Research
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
Abramson Cancer Center at Penn Medicine
ADCC
National Cancer Institute (NCI)
Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
Ohio State University Comprehensive Cancer Center
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer
Radiation Therapy Oncology Group
PACSA-ORL02
UNICANCER
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Stanford University
SGC-AX14
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Surgical Management of Multiple Mucoepidermoid Carcinoma and Adenocarcinoma
Ain Shams University
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
National Cancer Institute (NCI)
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Mayo Clinic
Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
University Health Network, Toronto
Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
University of Washington
Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
Medical University of South Carolina
PSMA-PET Imaging for Advanced ACC/SDC
Radboud University Medical Center
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Ohio State University Comprehensive Cancer Center
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
National Cancer Institute (NCI)
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Dana-Farber Cancer Institute
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Fox Chase Cancer Center
Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
Boston Medical Center
Iressa Study in Patients With Salivary Gland Cancer
M.D. Anderson Cancer Center
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
Alliance for Clinical Trials in Oncology